Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Phase 1

• Conditions: Advanced Gastric Carcinoma; First-line Treatment
• Interventions: Drug: Lenvatinib

• Registration Number: NCT05221775
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

This is a single center, prospective, open label phase I study evaluating the safety and tolerance of standard first-line chemotherapy XELOX regimen combined with GLS-010 (anti-PD-1 antibody) and different doses of Lenvatinib in the treatment of advanced AFP-positive gastric cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. In this study, patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined with GLS-010 plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/ m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with GLS-010 (240 mg, intravenous infusion, every 3 weeks) plus Lenvatinib whose dose is based on the '3 + 3' dose climbing mode (12mg, 16mg and 20mg respectively, orally once a day). Safety will be evaluated by AE and laboratory tests. Patients received regular and periodic reviews, with imaging evaluations every 6 weeks.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-01
• Status Verified: 2022-01
• Study First Submitted: 2022-01-23
• Study First Submitted QC: 2022-01-23
• Last Update Submitted: 2022-01-23
• Study First Posted: 2022-02-03
• Last Update Posted: 2022-02-03
• Primary Completion: 2023-03-01
• Study Completion: 2023-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Male or female patients ≥ 20 years old;
2. Patients with advanced / metastatic gastric cancer diagnosed by histopathology, without liver like differentiation, HER-2 negative, AFP ≥ 20ng / ml;
3. No previous palliative systemic treatment;
4. There are measurable metastatic lesions according to RECIST version 1.1;
5. ECOG physical status score is 0 or 1；
6. Normal organ function: Neutrophil count ≥ 1.2 × 109/L, Platelet count ≥ 100 × 109/L, Hemoglobin (HB) ≥ 80g/L, Total bilirubin ≤ 1.5mg/dl, AST and ALT ≤ 100 IU/L. If the abnormal liver function is due to liver metastasis, AST and ALT should be ≤ 200 IU/L, Creatinine ≤ 1.5 times* upper limit of normal, International standardization ratio (INR) ≤ 1.5
7. Urinary protein: meet one of the following conditions Urinary protein (test paper method) is 2 + or less, Urinary protein/creatinine (UPC) ratio < 3.5, Determination of 24-hour urinary protein, urinary protein ≤ 3500mg
8. Before receiving treatment, the patient has recovered the adverse events related to chemotherapy, radiotherapy and surgery to grade 1 or below (CTCAE 5.0);
9. For women with fertility potential with negative pregnancy test within 14 days before enrollment, male and female patients should agree to use appropriate contraceptive methods from the beginning of the first treatment to 120 days after the last treatment;
10. Patients who can take oral drugs;
11. Signed the informed consent.

Exclusion Criteria

1. Patients who received surgery and radiotherapy within 2 weeks before enrollment;
2. Patients who have previously been treated with Lenvatinib or any anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs;
3. Patients with uncontrollable hypertension (systolic blood pressure ≥ 160mmHg and diastolic blood pressure ≥ 90mmHg);
4. Patients with acute coronary syndrome (including myocardial infarction and unstable angina) who had undergone coronary angioplasty within 6 months before enrollment;
5. Patients with symptomatic brain metastases;
6. Patients with New York Heart Association (NYHA) grade II or above congestive heart failure or severe arrhythmia with severe cardiovascular damage in the past 6 months;
7. The patients had active malignancies in the past 24 months (except for melanoma in situ, basal cell carcinoma of the skin or squamous cell carcinoma or carcinoma in situ of the cervix)
8. The patients have severe (hospitalized) complications
9. Patients with a history of gastrointestinal perforation and/or gastrointestinal fistula within 6 months before enrollment;
10. Patients with active hepatitis;
11. Patients with a history of human immunodeficiency virus (HIV) infection;
12. Patients with symptoms or signs of active interstitial pulmonary disease;
13. Patients with autoimmune diseases or a history of chronic or recurrent autoimmune diseases;
14. Patients who need systemic corticosteroids (excluding temporary use for testing, prophylactic administration of allergic reactions or reduction of swelling associated with radiotherapy) or immunosuppressants, or patients who receive such treatment within 14 days before enrollment;
15. The patient has a history of (non-infectious) pneumonia requiring steroids or has a current history of pneumonia;
16. Patients who received live vaccine < 30 days before starting trial drug treatment;
17. The patient has serious non-healing wounds, ulcers or fractures;
18. Pregnant or lactating women;
19. The investigator determined that the patient is not suitable to be the subject of this trial;
20. Other circumstances that the investigator considers inappropriate to participate in the clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
experimental arm	Lenvatinib	-

Primary Outcome Measures

Name	Time	Method
adverse effect	24 months	Safety will be evaluated by AE and laboratory tests.

Secondary Outcome Measures

Name	Time	Method
OS	24 months	The time from the beginning of treatment to the time when the patient dies from any cause
PFS	24 months	The time from the beginning of treatment to the time when the disease progresses or the patient dies from any cause
ORR	24 months	the rate of patients with PR and CR

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital; 🇨🇳 Tianjin, China